Sibel Health's Wireless Sensor Gains FDA Qualification
The FDA has accepted Sibel Health’s Aria wireless sensor for its Clinical Outcome Assessment (COA) qualification program. The wearable sensor, which attaches to the chest, enables continuous patient monitoring and could signal a trend toward integrating real-time physiologic data with diagnostic workflows.
- The FDA's qualification is for the Medical Device Development Tools (MDDT) program, which validates tools for use in clinical trials to make device development more predictable and efficient. Sibel Health's Aria sensor is now the company's third technology accepted into the program, meaning the company is responsible for three of the eight total digital health technologies qualified by the FDA as of February 2026. - The Aria sensor is a wearable patch that adheres to the base of the neck, using acousto-mechanical sensing to capture the physical vibrations and sounds of a cough. This method allows for objective, continuous monitoring without recording ambient audio, addressing the privacy concerns often associated with 24-hour monitoring. - This regulatory milestone could position the Aria sensor as a potential industry standard for measuring cough frequency in clinical trials for chronic refractory cough, asthma, and COPD. This follows the company's previous FDA COA qualifications for a scratch sensor for atopic dermatitis and a swallow sensor for Parkinson's disease. - Sibel Health, a Northwestern University spin-out, has raised over $105 million and is backed by strategic investors including medical technology company Dräger, Samsung Next, and Japanese dermatology leader Maruho Co., Ltd. - The company's core platform, ANNE® One, already has multiple FDA 510(k) clearances for continuous monitoring of vital signs in patients from neonates to adults and is being deployed in US and European hospitals. - This move into remote monitoring for clinical trials reflects a broader industry shift toward decentralized data collection; the global health sensors market was valued at over $42 billion in 2023 and is projected to grow at a CAGR of 19.07% through 2030. - The competitive landscape for patient monitoring includes established players like Philips and GE HealthCare, but the rise of wearable sensors is creating opportunities for specialized companies like Sibel to provide objective data for both clinical care and pharmaceutical research.
